UNSPSC 51142525: Droxidopa

This classification denotes an antiparkinsonian agent with the molecular formula C9H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7A92W69L7, chemically known as (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine but generally known as droxidopa, which bears US NIH Compound Identifier 3171. European Medicines Agency schedules Droxidopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06420MIG.

UNSPSC 51142525 Droxidopa is a Commodity code that in practice does not align with actual state and local procurement activity. The single recent opportunity posted under this code—Seminole County, Florida's IFB60459723LAS, issued June 30, 2026—solicits naloxone and drug deactivation systems rather than droxidopa, an orthostatic hypotension medication. The mismatch between the code's nominal pharmaceutical scope and the naloxone procurement suggests either a coding error in the county's submission or inconsistent application of UNSPSC taxonomy in state and local procurement systems. Based on available records, this code shows no relevant recent activity for droxidopa or related medications in state and local contracting.

Seminole County, Florida's IFB called for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The solicitation required electronic bid submission, included E-Verify compliance and drug-free workplace certification, and offered a two-year initial term with a one-year renewal option. The procurement indicated potential FEMA funding with associated federal compliance obligations. Beyond this single misaligned opportunity, no other state or local droxidopa procurements appear in recent records.